Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.03.2022 | Case report

Antineoplastics

Deep vein thrombosis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Mocikova H, et al. Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?. Blood 138 (Suppl. 1): 4539 abstr. 624, 23 Nov 2021. Available from: URL: http://doi.org/10.1182/blood-2021-148363 [abstract] Mocikova H, et al. Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?. Blood 138 (Suppl. 1): 4539 abstr. 624, 23 Nov 2021. Available from: URL: http://​doi.​org/​10.​1182/​blood-2021-148363 [abstract]
Metadaten
Titel
Antineoplastics
Deep vein thrombosis: case report
Publikationsdatum
01.03.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-12018-6

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Antineoplastics

Case report

Dexamethasone

Case report

Rituximab

Case report

Tozinameran